Boston Scientific notes first implantation of PROMUS stent
Natick-based Boston Scientific Corp. announced the first implantation of the PROMUS Everolimus-Eluting Stent, making the medical device developer the only company to offer two distinct drug-eluting stent (DES) platforms.
Dr. Willibald Maier performed the operation at University Hospital in Zurich, Switzerland. The PROMUS stent received CE Mark approval in October of '06, allowing Boston Scientific to distribute the stent in select countries of the European Economic Area. The stent will also be available in selected countries in Asia, Latin America, and Eastern Europe, with a U.S. launch planned for 2008.
"The PROMUS Stent complements our broad DES portfolio and further reinforces Boston Scientific's leadership in the DES market, as well as our commitment to continued innovation," said Paul LaViolette, chief operating officer of Boston Scientific.
Earlier this week, Boston Scientific announced 500 to 600 layoffs of its cardiac rhythm management (CRM) research and development resources. Read more by clicking here.
WBJ Web Partners
Most Recent
Most Recent
0 Comments